Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 (hospitalized or not) meta-analysis

Ayerbe OBSanticoagulantcontrolCOVID-19 (hospitalized or not)NA
1857/162 suggested
  • suggested 35 % decrease in deaths
Gonzalez-Porras OBSanticoagulant, prophylactic dosecontrolCOVID-19 (hospitalized or not)NA
-/- suggested
  • suggested 43 % decrease in deaths
Gonzalez-Porras OBSanticoagulant, prophylactic doseanticoagulant, curative doseCOVID-19 (hospitalized or not)NA
-/- safety concern
  • statistically significant 44 % increase in deaths
Gonzalez-Porras OBSanticoagulant, curative dosecontrolCOVID-19 (hospitalized or not)NA
-/- suggested
  • suggested 60 % decrease in deaths
Rossi OBSanticoagulant, pre-admissioncontrolCOVID-19 (hospitalized or not)NA
-/- suggested
  • suggested 49 % decrease in deaths
Russo OBSanticoagulant, pre-admissioncontrolCOVID-19 (hospitalized or not)NA
-/- inconclusive
    Tremblay OBSanticoagulant, pre-admissioncontrolCOVID-19 (hospitalized or not)NA
    		-/- inconclusive
      Trinh OBSanticoagulant, prophylactic doseanticoagulant, curative doseCOVID-19 (hospitalized or not)NA
      		-/- safety concern
      • statistically significant 72 % increase in deaths

      PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
      Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

       

      - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons